Dosing & Uses
Dosage Forms & Strengths
powder for injection
Hormone-dependent Advanced Prostate Carcinoma (Stage D)
Initial: 120 mg SC for 2 doses (ie, 2 separate injections totaling 240 mg), THEN after 28 days, begin maintenance dose of 80 mg SC q28Days
≥50 mL/min: Dose adjustment not necessary
<50 mL/min: Use caution
Mild-to-moderate: Dose adjustment not necessary
Severe: Safety and efficacy not established; use caution
Initiation pack contains 2 vials each with 120 mg per vial & 6 mL sterile water for injection diluent
Withdraw 3 mL of sterile water for injection diluent (supplied) & add to 1 of the 2 vials, swirl to mix - keep vial vertical at all times, do not shake
Inject SC in abdomen within 1 hour of reconstitution
Repeat for 2nd injection and use different injection site
Maintenance pack contains 1 vial of 80 mg per vial & 4.2 mL sterile water for injection diluent
Use 4.2 mL to reconstitute, withdraw 4 mL for dose of 80 mg
Hot flashes (26%)
Injection site erythema (17%)
Injection site pain (28%)
Weight gain (11%)
Elev liver enzymes (10%)
Injection site induration/swelling
Pregnancy or in women who may become pregnant
Severe hepatic impairment
Long-term androgen deprivation treatment prolongs QT interval, this is increased risk with congenital long QT syndrome, electrolyte abnormalities, CHF, coadministration with antiarrhythmic agents from Class IA [eg, quinidine, procainamide)]or Class III [eg, amiodarone, sotalol]); consider whether benefits of androgen deprivation therapy outweigh potential risks
Bone mineral density may decrease due to androgen deprivation therapy
Risk for diabetes may increase due to androgen deprivation, which may cause obesity and insulin resistance
Hypersensitivity reactions (eg, anaphylaxis, urticaria, angioedema) reported; if a serious hypersensitivity reaction occurs, discontinue drug immediately if the injection has not been completed, and manage as clinically indicated; do not rechallenged
Pregnancy & Lactation
Pregnancy Category: X
Lactation: excretion in milk unknown/not recommended
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
GnRH receptor antagonist, suppresses testosterone production by decreasing LH and FSH
Protein Bound: 90%
Vd: >1000 L
Onset of action: Within 3 days
Metabolism: Liver by peptide hydrolysis
Excretion: Feces (70-80%), urine (20-30%)
Half-life elimination: Feces (75%); urine (25%)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs